Adaptimmune and TCR2 Merge to Form a Solid Tumour Company

By Shweta Gupta & Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)

Published: 28 Mar-2023

DOI: 10.3833/pdr.v2023.i3.2775     ISSN: 1756-7874

Section: Mergers & Acquisitions



In an all-stock transaction, Adaptimmune Therapeutics will merge with TCR2 Therapeutics to create a preeminent cell therapy company focused on treating solid tumours...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details